Orano Med
Sitasma Khatri is a QA Specialist II at Orano Med since July 2022, leading the overhaul of the vendor qualification system to enhance efficiency and communication in GMP compliance. Previously, Sitasma held positions at Merck as a Quality Assurance Specialist and Associate Specialist, where responsibilities included managing daily deviation meetings and approving critical documentation. Additional experience includes working in the emergency department at Carilion Clinic, serving as a graduate instructor in Advanced Human Physiology at Eastern Mennonite University, and providing documentation support for physician practices at On Demand Solutions, Inc. Sitasma holds a Master of Science in Biological and Biomedical Sciences from Eastern Mennonite University and a Bachelor of Science in Psychology from the University of Utah.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.